GLP-1 Drugs Show Real Promise for Obese Kids and Teens With Type 2 Diabetes
A systematic review of 13 studies finds semaglutide and liraglutide meaningfully cut BMI and improve blood sugar in children and adolescents.
Summary
Childhood obesity and youth-onset type 2 diabetes are rising sharply, yet treatment options beyond lifestyle changes and metformin remain limited. This systematic review examined how well GLP-1 receptor agonists — drugs like semaglutide and liraglutide — work in children and adolescents aged 6 to 17. Pooling data from seven randomized controlled trials and six meta-analyses involving 901 young patients, researchers found semaglutide 2.4 mg weekly produced the greatest BMI reductions in obese teens. Liraglutide improved BMI in both adolescents and younger children. For youth with type 2 diabetes, liraglutide and dulaglutide significantly lowered HbA1c versus placebo. Side effects were mainly nausea and vomiting, which were transient. Importantly, no harm to normal growth or puberty was detected, though longer-term safety data are still needed.
Detailed Summary
Childhood obesity and type 2 diabetes in young people have reached crisis proportions globally. For decades, clinicians had little to offer beyond lifestyle counseling and metformin, leaving many patients without adequate metabolic control. GLP-1 receptor agonists have transformed adult obesity and diabetes care, but their role in pediatric populations has been less clear — until now.
This systematic review from researchers at Hamad Medical Corporation in Qatar screened PubMed-indexed studies published between 2000 and 2025. The final analysis included seven pivotal randomized controlled trials and six meta-analyses, collectively enrolling 901 participants aged 6 to under 18 years with obesity, type 2 diabetes, or both.
Among the weight-focused findings, once-weekly semaglutide 2.4 mg produced the largest BMI reductions in obese adolescents. Daily liraglutide 3.0 mg also significantly reduced BMI standard deviation scores across adolescent and younger child cohorts. For youth-onset type 2 diabetes specifically, liraglutide 1.8 mg/day and dulaglutide both delivered meaningful HbA1c improvements over placebo. Secondary metabolic benefits included reductions in insulin resistance and modest decreases in triglycerides, though LDL-cholesterol changes were minimal.
On safety, gastrointestinal side effects — predominantly nausea and vomiting — were the most common adverse events and proved generally transient and dose-dependent. Critically, no significant negative effects on linear growth or pubertal development were observed across the reviewed studies, which is a central concern when intervening in developing children.
The clinical implications are meaningful: GLP-1 RAs appear to be effective and reasonably safe adjunct therapies for pediatric metabolic disease. However, the review's authors stress that the evidence base remains limited in scope. Longer-term trials are essential to fully characterize cardiovascular safety, effects on bone mineral density, and growth trajectories in this vulnerable population before broader prescribing can be confidently recommended.
Key Findings
- Semaglutide 2.4 mg/week produced the greatest BMI reduction among obese adolescents in the reviewed trials.
- Liraglutide and dulaglutide significantly improved HbA1c in youth-onset type 2 diabetes versus placebo.
- GLP-1 RAs modestly reduced triglycerides and insulin resistance; LDL changes were minimal.
- Nausea and vomiting were the most common side effects but were transient and dose-dependent.
- No significant harm to linear growth or pubertal progression was detected across 901 pediatric participants.
Methodology
This systematic review covered PubMed-indexed studies from 2000 to 2025, focusing on seven randomized controlled trials and six meta-analyses. The total participant pool was 901 children and adolescents aged 6 to under 18 years diagnosed with obesity or type 2 diabetes. Multiple GLP-1 agents were evaluated, including semaglutide, liraglutide, and dulaglutide.
Study Limitations
The summary is based on the abstract only, as the full text is not open access. The 901-participant pooled sample is relatively small for a pediatric population, and the included trials may vary substantially in duration and outcome definitions. The authors explicitly note that longer-term data on cardiovascular safety, bone health, and growth are lacking, limiting confidence in extended use recommendations.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: